AI-powered antibody therapeutics discovery company Ability Biologics has raised USD 18 million in a seed funding round led by Amplitude Ventures, with participation from Fonds de solidarité FTQ, Investissement Québec, Charles River Laboratories, Theodorus, and Alexandria Venture Investments.
The funds will be used to develop Ability's AI-enabled AbiLeap discovery platform, which generates logic-gated, fully human antibodies targeting specific tissues based on certain conditions, such as pH and temperature variations, for enhanced therapeutic selectivity and potency.
Canada-based Ability Biologics is focused on developing highly specific and selective antibody therapeutics to address unmet medical needs in cancer and autoimmune diseases. The company leverages its proprietary AbiLeap discovery platform, which uses AI and a database of antigen-antibody interactions.
By using this site, you agree to allow SPEEDA Edge and our partners to use cookies for analytics and personalization. Visit our privacy policy for more information about our data collection practices.